Pages with the fewest revisions
Jump to navigation
Jump to search
Showing below up to 50 results in range #64,251 to #64,300.
- Murder-suicide (5 revisions)
- Muscarinic acetylcholine receptor M5 (5 revisions)
- Muscle weakness CT (5 revisions)
- Muscle weakness and Neuropathy (5 revisions)
- Muscle weakness case study one (5 revisions)
- Muscle weakness chest x ray (5 revisions)
- Muscle weakness cost-effectiveness of therapy (5 revisions)
- Muscle weakness epidemiology and demographics (5 revisions)
- Muscle weakness future or investigational therapies (5 revisions)
- Muscle weakness historical perspective (5 revisions)
- Muscle weakness other diagnostic studies (5 revisions)
- Muscle weakness other imaging findings (5 revisions)
- Muscle weakness physical examination (5 revisions)
- Muscle weakness primary prevention (5 revisions)
- Muscle weakness risk factors (5 revisions)
- Muscle weakness screening (5 revisions)
- Muscle weakness secondary prevention (5 revisions)
- Musculoskeletal problems of the wrist and hand classification (5 revisions)
- Musculoskeletal system (5 revisions)
- Mushroom poisoning (5 revisions)
- Myalgia differential diagnosis (5 revisions)
- Myalgia future or investigational therapies (5 revisions)
- Myasthenia gravis other imaging findings (5 revisions)
- Mycobacterium abscessus historical perspective (5 revisions)
- Mycobacterium abscessus other imaging findings (5 revisions)
- Mycobacterium abscessus risk factors (5 revisions)
- Mycobacterium avium intracellulare (5 revisions)
- Mycobacterium immunogenum (5 revisions)
- Mycosis fungoides case study one (5 revisions)
- Mycosis fungoides electrocardiogram (5 revisions)
- Myocarditis cost-effectiveness of therapy (5 revisions)
- Myoclonus natural history, complications and prognosis (5 revisions)
- Myofascial pain syndrome (5 revisions)
- Myopericarditis (5 revisions)
- Myopia physical examination (5 revisions)
- Myopia primary prevention (5 revisions)
- Myotonia congenita (5 revisions)
- Myxedema coma epidemiology and demographics (5 revisions)
- Myxedema coma primary prevention (5 revisions)
- Myxoma cost-effectiveness of therapy (5 revisions)
- Myxoma future or investigational therapies (5 revisions)
- N-Acetylaspartylglutamate (5 revisions)
- NAD+ kinase (5 revisions)
- NEXOBRID (5 revisions)
- NF-κB (5 revisions)
- NPM1 (5 revisions)
- NRF1 (5 revisions)
- Nadifloxacin (5 revisions)
- Naegleria infection causes (5 revisions)
- Naegleria infection cost-effectiveness of therapy (5 revisions)